Skip to main content
SpringerLink
Log in

Malignant melanoma in natalizumab recipients with MS

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Kelm RC, et al. Melanoma subsequent to natalizumab exposure: A report from the RADAR (Research on Adverse Drug events And Reports) Program. Journal of the American Academy of Dermatology : 2 Nov 2018. Available from: URL: http://doi.org/10.1016/j.jaad.2018.10.052

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Malignant melanoma in natalizumab recipients with MS. Reactions Weekly 1728, 10 (2018). https://doi.org/10.1007/s40278-018-54273-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-54273-2

Search

Navigation